Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Toronto
$27,000.00
Identifying the Role of NUAK and MARK Kinases in YAP-Mediated Chemoresistance in Colorectal Cancer
FY 2025-26
Summary
Colorectal cancer (CRC) is one of the most prevalent and lethal cancers worldwide. However, therapeutic efficacy remains limited, as a subset of CRC tumour cells exhibit significant resistance to chemotherapy, the current standard of care, increasing cancer persistence and relapse. The Hippo pathway is a key regulator of cell proliferation, and its dysregulation drives the expression of genes implicated in the progression of almost all human cancers. We have identified several genes that inactivate the Hippo pathway. When inhibited, these genes, particularly the NUAK1/2 kinases and mitogen activated protein kinases 1-4 (MARK1-4), impair CRC tumour growth. Preliminary research suggests NUAK/MARK inhibitors prevent CRC tumour regrowth after treatment with traditional DNA-damaging chemotherapeutic agents, such as 5-fluorouracil. Recently, chemotherapeutic resistance and failure have been attributed to stem cell populations, particularly revival stem cells (RSCs) and cancer stem cells (CSCs). Unlike CSCs, RSCs depend on the Hippo pathway, resist traditional chemotherapeutic agents, and can regenerate CSCs. Thus, I hypothesize that NUAK/MARK kinases promote chemoresistance by sustaining Hippo pathway transduction, supporting the survival and conversion of revival stem cells into proliferative cancer stem cells during and after chemotherapeutic treatment. I propose to establish and exploit a chemoresistance model in CRC-Patient-Derived Organoids to evaluate the effect of NUAK/MARK inhibition on 5-fluorouracil chemotherapeutic treatment and Hippo activity. I also aim to explore how cancer stem cell plasticity mediates chemoresistance. In addressing the problem of drug resistance in CRC, my work has the potential to improve long term treatment outcomes and reduce relapse rates.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
573223
Name
Apanasevich Agata
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying the Role of NUAK and MARK Kinases in YAP-Mediated Chemoresistance in Colorectal Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cancer Stem Cells; Colorectal Cancer; Hippo Pathway; Kinases; Patient-Derived Organoids; Protein-Protein Interactions; Revival Stem Cells; Signal Transduction; Small Molecule Inhibitors; Therapeutic Resistance
Abstract
Colorectal cancer (CRC) is one of the most prevalent and lethal cancers worldwide. However, therapeutic efficacy remains limited, as a subset of CRC tumour cells exhibit significant resistance to chemotherapy, the current standard of care, increasing cancer persistence and relapse. The Hippo pathway is a key regulator of cell proliferation, and its dysregulation drives the expression of genes implicated in the progression of almost all human cancers. We have identified several genes that inactivate the Hippo pathway. When inhibited, these genes, particularly the NUAK1/2 kinases and mitogen activated protein kinases 1-4 (MARK1-4), impair CRC tumour growth. Preliminary research suggests NUAK/MARK inhibitors prevent CRC tumour regrowth after treatment with traditional DNA-damaging chemotherapeutic agents, such as 5-fluorouracil. Recently, chemotherapeutic resistance and failure have been attributed to stem cell populations, particularly revival stem cells (RSCs) and cancer stem cells (CSCs). Unlike CSCs, RSCs depend on the Hippo pathway, resist traditional chemotherapeutic agents, and can regenerate CSCs. Thus, I hypothesize that NUAK/MARK kinases promote chemoresistance by sustaining Hippo pathway transduction, supporting the survival and conversion of revival stem cells into proliferative cancer stem cells during and after chemotherapeutic treatment. I propose to establish and exploit a chemoresistance model in CRC-Patient-Derived Organoids to evaluate the effect of NUAK/MARK inhibition on 5-fluorouracil chemotherapeutic treatment and Hippo activity. I also aim to explore how cancer stem cell plasticity mediates chemoresistance. In addressing the problem of drug resistance in CRC, my work has the potential to improve long term treatment outcomes and reduce relapse rates.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Apanasevich, Agata
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~